Centre Hospitalier Universitaire De Poitiers
- Address
- lock Available on a paid plan
Oncology and Solid Tumors
The Service d’oncologie médicale at Centre Hospitalier Universitaire De Poitiers is highly active in oncology, with a strong focus on a wide range of solid tumors and advanced cancers. Research here includes studies aimed at testing new treatment strategies, improving disease control, and comparing emerging therapies with current standards of care.
- Breast, lung, gastrointestinal, and genitourinary cancers
- Rare and difficult-to-treat tumors such as sarcomas, neuroendocrine cancers, and biliary tract cancers
- Trials exploring better treatment effectiveness, recurrence prevention, and personalized cancer care
Much of the work centers on advanced or metastatic disease, reflecting the site’s broad role in evaluating innovative options for patients with limited treatment choices.
Hematology and Blood Disorders
Another major research area is hematology, covering both malignant and non-malignant blood disorders. The site contributes to studies in leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and amyloidosis, with the goal of improving survival, reducing symptoms, and refining long-term disease control.
- Acute and chronic leukemias, including acute lymphoblastic leukemia and acute myeloid leukemia
- Lymphomas, multiple myeloma, myelodysplastic syndromes, and myelofibrosis
- Research on treatment effectiveness, transplant-related care, and better supportive approaches
This hematology portfolio shows a strong interest in both newly diagnosed and relapsed disease, including studies designed to improve outcomes in Centre Hospitalier Universitaire De Poitiers patients with complex hematologic conditions.
Cardiovascular and Metabolic Research
The site also supports substantial research in cardiovascular disease and related metabolic disorders. Trials address conditions such as myocardial infarction, heart failure, hypertension, atherosclerosis, thrombosis, and diabetes, often with the aim of preventing complications and improving long-term outcomes.
- Acute coronary syndromes, stroke, and other vascular events
- Heart failure, valvular disease, hypertension, and cardiomyopathy
- Studies evaluating prevention strategies, treatment effectiveness, and risk reduction
Research in this area combines acute care and chronic disease management, highlighting the center’s interest in both immediate intervention and long-term cardiovascular protection.
Autoimmune, Inflammatory, and Rheumatologic Diseases
Clinical research at Centre Hospitalier Universitaire De Poitiers extends to immune-mediated diseases, including rheumatology, systemic autoimmune disorders, and inflammatory conditions. These studies aim to improve symptom control, reduce disease activity, and evaluate more targeted treatment options.
- Systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, and juvenile idiopathic arthritis
- Vasculitis, systemic sclerosis, myelitis, and other inflammatory syndromes
- Trials focused on better disease control, safer treatment options, and improved quality of life
This research area reflects a strong commitment to chronic conditions where immune system regulation is central to care.
Respiratory, Infectious, and Critical Care Medicine
The site has an active portfolio in respiratory medicine, infectious diseases, and critical care. Research includes severe infections, pneumonia, influenza, chronic lung disease, pulmonary hypertension, and intensive care complications, with a strong emphasis on improving outcomes in hospitalized and critically ill patients.
- COVID-19, sepsis, pneumonia, and bloodstream or postoperative infections
- COPD, asthma, bronchiectasis, pulmonary hypertension, and interstitial lung disease
- Studies testing new ways to treat infection, reduce complications, and support critically ill patients
These trials often address urgent clinical problems where timely treatment and better supportive care can make a major difference.
Neurology, Ophthalmology, and Other Specialized Fields
Beyond its major disease areas, the research environment at this hospital includes neurology, eye diseases, and several other specialized fields. Studies cover Parkinson’s disease, multiple sclerosis, stroke, macular degeneration, and rare neurological or pediatric conditions, often focusing on treatment effectiveness or better disease monitoring.
- Parkinson’s disease, multiple sclerosis, stroke, and traumatic brain injury
- Macular degeneration, diabetic macular edema, and retinoblastoma
- Trials aimed at improving diagnosis, symptom control, and functional outcomes
Across these diverse areas, the site’s research reflects a broad clinical mission that combines innovation in medical oncology with important work in chronic disease management and supportive care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 32 therapeutic areas and 15 of 722 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 671 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 146 by active trials.
lock +145 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +89 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire De Poitiers
lock Showing 1 of 633 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 722 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 59 | Unknown | 2014-12-23 | 2026-07-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
